Figure 1.
Map of Zambia showing the study area (Vulamkoko catchment) in Katete district of the Eastern province.
Figure 2.
Cohort composition and changes during the three sampling rounds.
(Format adapted from Garcia et al., 2003 [18]). R1, R2 and R3 stand for first, second and third round of sampling. Ag-ELISA: detection of circulating cysticercus antigen in serum; EITB: detection of specific antibodies in serum; HH QS = household questionnaire; Coprology: coproscopy and Copro-Ag-ELISA. *Only carried out on a randomly selected sample of 161. **Carried out on stool samples collected at R3.
Table 1.
Sero-antigen and sero-antibody cysticercosis prevalences for the three sampling rounds.
Figure 3.
Sero- antigen and antibody conversion and -reversion for the three periods.
SC and SR stand for seroconversion and seroreversion, respectively. P1 stands for period 1 (between Round 1 and Round 2, 6 months), P2 for period 2 (Round 2–3, 6 months) and P3 for period 3 (Round 1–3, 12 months). Ag-ELISA: detection of circulating cysticercus antigen in serum; EITB: detection of specific antibodies in serum.
Figure 4.
Sero-antigen conversion and -reversion in function of age categories for Period 3.
SC and SR stand for seroconversion and seroreversion, respectively.
Table 2.
Seroconversion rates of human cysticercosis in function of sex for both circulating antigen and specific antibody analyses.
Table 3.
Infection/exposure status changes based on sero-antigen and sero-antibody analysis throughout the study period.